FGFR1 amplification or overexpression is prevalent in various tumor types, with the highest rates observed in lung squamous cell carcinoma, breast cancer, bladder cancer, head and neck squamous cell carcinoma, and endometrial cancer. This evidence concerns the gene FGFR1 and breast cancer.